TENAX THERAPEUTICS, INC. 8-K

What Happened Tenax Therapeutics, Inc. reported the results of its June 2, 2026 annual meeting of stockholders (filed on Form 8-K, Item 5.07). Stockholders elected seven directors to one-year terms expiring in 2027, and ratified Cherry Bekaert LLP as the company’s independent registered public accounting firm for 2026.

Key Details

• Director election vote totals (For / Withheld / Broker Non-Votes = 3,742,678):
  • June Almenoff: 17,362,177 For; 214,449 Withheld
  • Michael Davidson: 15,762,162 For; 1,814,464 Withheld
  • Declan Doogan: 17,394,626 For; 182,000 Withheld
  • Christopher T. Giordano: 17,397,265 For; 179,361 Withheld
  • Robyn M. Hunter: 17,394,848 For; 181,778 Withheld
  • Gerald T. Proehl: 17,393,189 For; 183,437 Withheld
  • Stuart Rich: 17,397,413 For; 179,213 Withheld
• Auditor ratification vote (for 2026): 21,304,543 For; 3,688 Against; 11,073 Abstain; Broker Non-Votes: None.

Why It Matters These votes finalize Tenax’s board composition for the coming year and confirm the independent auditor, both routine but material governance actions investors monitor. The tallies show broad shareholder support for the director slate and near-unanimous ratification of Cherry Bekaert LLP, which affects corporate oversight and financial reporting continuity.